IPIX, with insufficient financial resources to develop their own products (per previous SEC filings), is committing $4 million cash for a minority stake in a private start-up in an unrelated field. All done on the cusp of a global recession (if not depression).

This will be epic!

Has there been a substantive PR since the covid failure?

I keep getting this nagging thought that you are totally right, and that Leo has gotten honest advice from Degado, and the advice is that the OM route is not very productive, an IV for ABSSSI is a nonstarter, that the IBD route is not relevant, and that Kevetrin is too many days late and too many dollars short. Not quite sure I buy this story, but he and a friend keep diluting us out of the game, and nothing changes. A coming half a billion outstanding shares would not get shareholders much, even if something panned out for a 30-40 million sale (and really, how likely is this?). Does this negative narrative include Alfasigma too? I have no idea, but it is all that remains of my realistic hope, I'm afraid. Some mildly hopeful invitro bacterial and viral tests really are so far from products that they are not worth spending too much thoughts on. In other words maybe the attempts at deals with BP, BARDA, etc. have been tried, and nothing has come of it all. And Leo will never be straight with us as long as he can belly up to the paymaster. Sure he has lots of shares, but if he has written it all off, how would he be acting, maybe just like he is now?

*LE, can U secure $$$??? Probably not.
*Can U drain out SHs $$$??? Absolutely!
*At least can U learn few things..how these guys were able to secure$$$? I'm too old for that and I'm happy with my nest egg (SHs $$).. hahaha


Pharma industry-backed fund invests in two biotech companies to treat 'superbugs...

MRSA (Methicillin-resistant Staphylococcus aureus) bacteria strain is seen in a petri dish containing agar jelly for bacterial culture in a microbiological laboratory in Berlin March 1, 2008. MRSA is a drug-resistant "superbug", which can cause deadly infections. REUTERS/Fabrizio Bensch

April 4 (Reuters) - A $1 billion fund backed by over 20 drugmakers made its first set of investments on Monday in two biotechnology startups, nearly two years after it was launched to help struggling antibiotic makers tackle the threat of antibiotic-resistant bacteria.

The AMR Action fund invested $20 million in Adaptive Phage Therapeutics as part of an ongoing series B round and spent an undisclosed amount in a series C round for Venatorx Pharmaceuticals. The fund plans to invest over $100 million by the end of the year.

I’ve reported Leo to the FBI. They were very interested in his potential ties to Russia.

Progress in the Brilacidin antiviral program largely will be dependent upon obtaining government funding for additional clinical development and leveraging external research relationships. Going forward, our business focus will be to advance Brilacidin in other disease areas and to pursue new business opportunities through joint ventures and other investments.

Is this great news or what?

Let's hope Leo is compiling info from multiple sources and will put out a PR that will be more like dynamite going off rather than a firecracker.

what exactly does limp dack Leo do all day? seriously? nothing has happened with this POS in 3 months

I agree bankruptcy would wipe out shareholders and the ones that want it are vultures looking to pick at the carcus

Careful what you wish for. That would be the end of our investment. IPIX would head straight to $0.01 on that news. Even if you got some new CEO, the first thing they will do is wipe out existing shareholders either with BK or a reverse split and secondary. Leo is sadly still our best hope.

but at this point we need Leo to step down

You expect Omicron testing? What happened to the Delta testing?

From IPIX on August 2nd (18 weeks ago):
Quote:
Related, the Company is in queue for in vitro testing of Brilacidin against the Delta (B.1.617.2) variant, . . .

Innovation Pharmaceuticals Provides Update on Brilacidin Antiviral Research

Results? . . . crickets . . .

Thoughtful post. Your last sentence sums up the mistake that so many retail investors, including myself, make: they think “hope” is a key part of an investment strategy. Smart money is dispassionate.

Smart money, in addition to researching the competitive landscape, understands dilution/predatory financing, reads source SEC filings, and comprehends research and how data extrapolates to the real world (e.g., the paper published in viruses strongly suggested [screamed?] that brilacidin would not work in the clinical trial as designed by IPIX).

Can a case can be made for buying IPIX at these prices? One argument would be that IPIX must raise the closing price to be >$0.10/share in order to access the Aspire financing. IPIX is dead in the water without the Aspire money. If you bought at $0.067 and sold at $0.10 you would make almost 50%. That’s pretty good if it happens. What are the counter arguments? Reverse stock split (1:2 means your basis doubled while the Aspire deal can still take place at $0.10)? Company sold for $0.05/share? CEO becomes incapacitated and sp craters? Company goes into suspended animation until patents/licenses run out?

BTW: The Aspire deal ends in late July. The money comes from Aspire in a dribble, not a gusher, so IPIX will need a significant number of trading days to achieve their financing needs. And there will be dilution, oh yeah. For example, if IPIX gets the sp above $0.10/share and starts putting the shares to Aspire on January 10th, and wants to access the full $25.4 million between then and end of July, and the share price averages $0.15/share during that period, there will be average daily dilution of >1.2 million shares.

35 posts today in 21.75 hours. Boils down to ~ 1 post every 33 minutes.

No interest… for good reason.

This goose is cooked.

This is painful to watch. Who is writing these horrid press releases?

Who is devising their dartboard strategy?

They’ve had 2 years to plan and now it looks as if they have zero plans and have been playing by the pool.

In two words it’s: embarrassing and pathetic.

Two follow up PRs after the one that cratered this stock smells like CPA desperation

According to the latest 10-Q, IPIX is still developing an oral rinse formulation for OM and they have the “potential to progress” to a P3 sometime in 2022.

Was LW ever even in the car???

Only Leo can drag a trial with Fast Track this long in a pandemic.

When would this happen?

This platform is worthy of further investigation but not by this carnival

...we must make sure CEO and others in the management clarifies and provide answers to those questions raised!!

Game over IPIX, Let the lawsuits begin.

This information was included in the IPIX 10-K for the period ended June 30, 2021. You can claim it was "buried", but SEC filings are required reading for investors.

From the 10-K
Quote:
IBD, Ulcerative Colitis (UC) — Brilacidin is also being developed as a treatment in more extensive forms of IBD.

Development of a delayed release oral formulation has been in progress, with development work expanding into immediate release formulations due to unexpected findings encountered. Such findings appear due to the inherent physiochemical properties of the compound, and those of polymers used to achieve delayed release. An immediate release, multi-particulate capsule formulation has been developed and a ‘research and development’ batch has progressed to stability testing at the manufacturing vendor. Further work is ongoing, in preparation for manufacture of clinical trial supplies.

Based on these recent findings, the development plan for ulcerative colitis has been adapted with inclusion of Phase 1 testing of the immediate release oral formulation. Clinical trials will be able to progress pending completion of clinical trial supply manufacturing (currently scheduled for January 2022) and securing sufficient working capital.

“In its letter, the FDA noted that so far, it has reviewed safety in only 131 randomized patients treated with ZYESAMI.”

https://www.prnewswire.com/news-releases/us-food-and-drug-administration-declines-emergency-use-authorization-for-zyesami-aviptadil-for-patients-with-critical-covid-19-with-respiratory-failure-301417228.html?fbclid=IwAR3_cYj8GViBA0asnnbjHH0kFfyXoeb4EyGaOZWqHmTWDmrpS8AWw3Y5Rg8

Note the use of the word “only”.

In IPIX’ study, only around 60 patients with COVID-19 will have received brilacidin.

CI start and end date
12/17/2020 - 12/31/2021

Number of patients
138

"Other than a similar name to ipix there appears to be no connection."

I think the connection is pretty strong. Ipharm is IPIX's Russian CRO.

Organization involved by the drug developer
IPharma LLC, 143026, Moscow, the territory of the Skolkovo innovation center, st. Nobel, 7, Russia

https://clinline.ru/reestr-klinicheskih-issledovanij/705-17.12.2020.html

Then why are you here dude? About three weeks until some news that many of us hope will be amazing.

Again, that’s Leo Ehrlich. He is the sole person in control of how quickly- or how soul destroyingly, sluggishly, painfully slowly the efficacy or otherwise of brilacidin is determined.

On the plus side for Leo, every day this question goes unanswered is worth a couple of thousand bucks to him in salary, and maybe more in share sales and kickbacks from Kips’ Bay and Aspire.

I think this might be remembered as the day Leo Ehrlich "jumped the shark".

"CEO Employment Agreement — The Compensation Committee approved, and the Board of Directors ratified"

What Compensation Committee?

LOL!

https://www.sec.gov/Archives/edgar/data/1355250/000147793221007301/ipix_8k.htm

The best and most spectacularly egregious bit:

"A. Section 4 of the Plan is amended and restated in its entirety to read as follows:



“4. Shares Subject to the Plan.



4.1 Subject to adjustment in accordance with Section 11, a total of 225,000,000 shares of Common Stock shall be available for the grant of Awards under the Plan; provided that no Outside Director may be granted Awards covering more than 5,000,000 shares of Common Stock in any year. Any shares of Common Stock granted in connection with Options, Stock Appreciation Rights or other Awards shall be counted against this limit as one (1) share of Common Stock granted in connection with such Award. During the terms of the Awards, the Company shall keep available at all times the number of shares of Common Stock required to satisfy such Awards.



4.2 Shares of Common Stock available for distribution under the Plan may consist, in whole or in part, of authorized and unissued shares, treasury shares or shares reacquired by the Company in any manner.



4.3 Subject to adjustment in accordance with Section 11, no Participant shall be granted, during any one (1) year period, Options to purchase Common Stock and Stock Appreciation Rights with respect to more than 200,000,000 shares of Common Stock in the aggregate or any other Awards with respect to more than 200,000,000 shares of Common Stock in the aggregate. If an Award is to be settled in cash, the number of shares of Common Stock on which the Award is based shall count toward the individual share limit set forth in this Section 4.



4.4 Any shares of Common Stock subject to an Award that is canceled, forfeited or expires prior to exercise or realization, either in full or in part, shall again become available for issuance under the Plan. Notwithstanding anything to the contrary contained herein: shares subject to an Award under the Plan shall not again be made available for issuance or delivery under the Plan if such shares are (a) shares tendered in payment of an Option, (b) shares delivered or withheld by the Company to satisfy any tax withholding obligation, or (c) shares covered by a stock-settled Stock Appreciation Right or other Awards that were not issued upon the settlement of the Award.”
[/url][tag]insert-text-here[/tag]


B. Section 7.4(d)(vi) of the Plan is amended and restated in its entirety to read as follows:


(vi) Maximum Award Payable



Notwithstanding any provision contained in this Plan to the contrary, the maximum Performance Compensation Award payable to any one Participant under the Plan for a Performance Period (excluding any Options and Stock Appreciation Rights) is 200,000,000 shares of Common Stock or, in the event such Performance Compensation Award is paid in cash, the equivalent cash value thereof on the first or last day of the Performance Period to which such Award relates, as determined by the Committee. The maximum amount that can be paid in any calendar year to any Participant pursuant to a cash bonus Award described in the last sentence of Section 7.4(a) shall be $40,000,000. Furthermore, any Performance Compensation Award that has been deferred shall not (between the date as of which the Award is deferred and the payment date) increase (A) with respect to a Performance Compensation Award that is payable in cash, by a measuring factor for each fiscal year greater than a reasonable rate of interest set by the Committee or (B) with respect to a Performance Compensation Award that is payable in shares of Common Stock, by an amount greater than the appreciation of a share of Common Stock from the date such Award is deferred to the payment date.”"

https://www.sec.gov/Archives/edgar/data/1355250/000147793221007301/ipix_ex101.htm

Why fail to move B UC forward in that 18 months IP? Why?

I've long felt that B for IBD-related issues could be the defining moments for IPIX. This recent journal article emphasizes what seem to be the strong suits of B for IBD related issues. We can only hope Leo find the money and the wisdom to follow through here effectively...

Terrible decision if you ask me. That person will be very sorry in less than a month!

Todays low of .2016 is still a higher low by .0016.

Possibly the bottom of .20 will hold for the rebound into the .30's. Decent data and this may be on its way to the $$$$ land.

Good morning. New Covid cases in the U.S. have fallen by more than a third in the past month.


The reasons remain somewhat unclear, and there is no guarantee that the decline in caseloads will continue. But the turnaround is now large enough — and been going on long enough — to deserve attention.

The number of new daily cases in the U.S. has fallen 35 percent since Sept. 1:


Worldwide, cases have also dropped more than 30 percent since late August. “This is as good as the world has looked in many months,” Dr. Eric Topol of Scripps Research wrote last week.

These declines are consistent with a pattern that regular readers of this newsletter will recognize: Covid’s mysterious two-month cycle. Since the Covid virus began spreading in late 2019, cases have often surged for about two months — sometimes because of a variant, like Delta — and then declined for about two months.

Epidemiologists do not understand why. Many popular explanations, like seasonality or the ebbs and flows of social distancing, are clearly insufficient, if not wrong. The two-month cycle has occurred during different seasons of the year and occurred even when human behavior was not changing in obvious ways.

The most plausible explanations involve some combination of virus biology and social networks. Perhaps each virus variant is especially likely to infect some people but not others — and once many of the most vulnerable have been exposed, the virus recedes. And perhaps a variant needs about two months to circulate through an average-sized community.

Human behavior does play a role, with people often becoming more careful once caseloads begin to rise. But social distancing is not as important as public discussion of the virus often imagines. “We’ve ascribed far too much human authority over the virus,” as Michael Osterholm, an infectious-disease expert at the University of Minnesota, has told me.

The recent declines, for example, have occurred even as millions of American children have again crowded into school buildings.

Hospitalizations, too
Whatever the reasons, the two-month cycle keeps happening. It is visible in the global numbers, as you can see in the chart below. Cases rose from late February to late April, then fell until late June, rose again until late August and have been falling since.


The pattern has also been evident within countries, including India, Indonesia, Thailand, Britain, France and Spain. In each of them, the Delta variant led to a surge in cases lasting somewhere from one and a half to two and a half months.

In the U.S., the Delta surge started in several Southern states in June and began receding in those states in August. In much of the rest of the U.S., it began in July, and cases have begun falling the past few weeks. Even pediatric cases are falling, despite the lack of vaccine authorization for children under 12, as Jennifer Nuzzo of Johns Hopkins University told The Washington Post. (You can see the overall trends for every state here.)

The most encouraging news is that serious Covid illnesses are also declining. The number of Americans hospitalized with Covid has fallen about 25 percent since Sept. 1. Daily deaths — which typically change direction a few weeks after cases and hospitalizations — have fallen 10 percent since Sept. 20. It is the first sustained decline in deaths since the early summer.


‘The last major wave’?
This is the part of the newsletter where I need to emphasize that these declines may not persist. Covid’s two-month cycle is not some kind of iron law of science. There have been plenty of exceptions.

In Britain, for example, caseloads have seesawed over the past two months, rather than consistently fallen. In the U.S., the onset of cold weather and the increase in indoor activities — or some other unknown factor — could cause a rise in cases this fall. The course of the pandemic remains highly uncertain.

But this uncertainty also means that the near future could prove to be more encouraging than we expect. And there are some legitimate reasons for Covid optimism.

The share of Americans 12 and over who have received at least one vaccine shot has reached 76 percent, and the growing number of vaccine mandates — along with the likely authorization of the Pfizer vaccine for children ages 5 to 11 — will increase the number of vaccinations this fall. Almost as important, something like one-half of Americans have probably had the Covid virus already, giving them some natural immunity.

Eventually, immunity will become widespread enough that another wave as large and damaging as the Delta wave will not be possible. “Barring something unexpected,” Dr. Scott Gottlieb, a former F.D.A. commissioner and the author of “Uncontrolled Spread,” a new book on Covid, told me, “I’m of the opinion that this is the last major wave of infection.”

Covid has not only been one of the worst pandemics in modern times. It has been an unnecessarily terrible pandemic. Of the more than 700,000 Americans who have died from it, nearly 200,000 probably could have been saved if they had chosen to take a vaccine. That is a national tragedy.

Covid also isn’t going to disappear anytime soon. It will continue to circulate for years, many scientists believe. But the vaccines can transform Covid into a manageable disease, not so different from a flu or common cold. In the past few weeks, the country appears to have moved closer to that less grim future.

Whatever this autumn brings, the worst of the pandemic is almost certainly behind us.

Best part is: It's a pill... (no hospital visit to get Uncle Leo's magic anti-everything Elixer injected into you... )

I would like to see the side effects....from what I read, you have a 50/50 chance of surviving covid, but a chance of getting cancer.

small molecules like molnupiravir are less specific and run a higher risk of off-target side effects, University of North Carolina immunology and infectious diseases researcher Dr Sam Lai added. Molnupiravir is an oral ribonucleoside analog that inhibits RNA virus replication. The drug has certain mutagenic characteristics whereby human cells can also be targeted so there is a theoretical potential for causing genetic alterations, or potentially cancers

In an interim analysis of a Phase 3 trial involving patients with mild-to-moderate COVID-19, Merck’s drug molnupiravir was found to have cut the risk of hospitalization or death by 50%.

It's dropping because there's other therapeutics hitting the market soon... Unless Leo gets emergency use data will not matter... A phase 3 is not in-the-cards... Been saying this for a year... The costs and time to complete would not be worth the revenue potential which is a big fat DON'T KNOW or HAVE a CLUE...